SCHEDULE: Millennium Management Discloses 4.0% Stake in Cumberland Pharma
Beneficial Ownership Report (Schedule 13G)
Millennium Management and affiliated entities reported a 4.0% passive beneficial ownership stake in Cumberland Pharmaceuticals Inc. as of September 30, 2025.
Summary
- Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 598,634 shares of Cumberland Pharmaceuticals Inc. Common Stock.
- This aggregate amount represents 4.0% of the class of securities.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a passive investment.
- The reporting persons explicitly certified that the securities were not acquired or held for the purpose of changing or influencing control of Cumberland Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of passive beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- A prominent institutional investor group, including Millennium Management LLC, has disclosed a significant 4.0% stake in Cumberland Pharmaceuticals Inc., which may signal institutional interest in the company.
Future Outlook
NA
Management Comments
- Gil Raviv, Global General Counsel for Integrated Core Strategies (US) LLC, Millennium Management LLC, and Millennium Group Management LLC, certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
- Israel A. Englander, as a reporting person, also certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Industry Context
NA
Stakeholder Impact
- Shareholders may note the disclosed institutional ownership by Millennium Management and its affiliates, which could be interpreted as a sign of market interest in Cumberland Pharmaceuticals Inc.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement |
| 10/29/2025 | Date of Joint Filing Agreement and signature date for the Schedule 13G |
Keywords
Cumberland Pharmaceuticals, Millennium Management, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.